This site is intended for Healthcare Professionals only. if you are a member of the general public, click here
Patients on ZEPOSIA achieved rapid symptomatic relief one week after
completing the 7-day dose titration (post hoc analysis)1
Symptomatic response* in the
TRUE NORTH induction period†
Adapted from Siegmund B et al. 2022.1
Pinch & zoom to explore
Patients on ZEPOSIA achieved higher rates of symptomatic remission vs placebo as early as Week 5 after treatment initiation (post hoc analysis)1
Pinch & zoom to explore
Adapted from Siegmund B et al. 2022.1
*Symptomatic response was defined as a decrease from baseline of ≥1 point and ≥30% in the adapted partial Mayo score (sum of the RBS, SFS, and Physician Global Assessment subscore, ranging from 0–9 points) and a decrease of ≥1 point from baseline in RBS or an absolute RBS ≤1 point.1
†Data are based on the non-responder imputation.1
‡Symptomatic remission was defined as a RBS of 0 points and a SFS ≤1 point (and a decrease of ≥1 point from the baseline SFS).1
CI, confidence interval; RBS, rectal-bleeding subscore; SFS, stool-frequency subscore.
Reference
- Siegmund B et al. Poster presented at: European Crohn’s and Colitis Organisation, Virtual; 16–19 February, 2022. Poster: DOP43.
Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Ireland-via HPRA Pharmacovigilance at www.hpra.ie Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK);
© 2024 Bristol-Myers Squibb Company. All rights reserved.
Job: 2084-GB-2300276 Date of Preparation: June 2023